Continuous intravenous tirofiban can improve the 90-day functional outcome and decrease 90-day mortality without increasing bleeding risk in acute ischemic stroke patients treated by endovascular therapy: A meta-analysis

替罗非班 医学 改良兰金量表 优势比 随机对照试验 内科学 冲程(发动机) 脑出血 麻醉 外科 蛛网膜下腔出血 缺血 缺血性中风 心肌梗塞 机械工程 经皮冠状动脉介入治疗 工程类
作者
Aiwu Zhang,Nihong Wu,Xintong Liu,Tao Jiang
出处
期刊:Journal of Clinical Neuroscience [Elsevier BV]
卷期号:99: 109-116 被引量:7
标识
DOI:10.1016/j.jocn.2022.03.008
摘要

Background The role of continuous intravenous administration of tirofiban in endovascular therapy is still unclear. This meta-analysis aims to evaluate the 90-day functional prognosis in acute ischemic stroke patients (AIS) treated by endovascular treatment and intravenous administration of tirofiban. Methods We searched PubMed, Embase, and CENTRAL databases with the subject terms “tirofiban”, “brain ischemia”, and some related free words. Inclusion criteria were: (1) cohort study or randomized control trials; (2) AIS patients who received endovascular therapy; (3) the intervention or exposure was intravenous tirofiban monotherapy or combined with intra-arterial tirofiban; (4) containing data on modified Rankin Scale at 90 days and including at least one of the following indicators: mortality, symptomatic intracranial hemorrhage (sICH), intracranial hemorrhage (ICH), and recanalization. A summary odds ratio was calculated. Results Twelve eligible studies, consisting of 3268 AIS participants, were identified. There was a significant trend of favorable outcomes (measured by mRS at three months) in the tirofiban group (ORs = 1.36; 95% CI = 1.09–1.70). In addition, compared with the non-tirofiban group, intravenous tirofiban was significantly associated with decreased risk of 90-day mortality (ORs = 0.73; 95% CI:0.59–0.89) and increased recanalization rate (ORs = 1.50; 95% CI:1.08–2.09) but no significant difference in rates of sICH (ORs = 0.93; 95% CI = 0.70–1.24) or ICH (ORs = 0.84; 95% CI = 0.62–1.15). Conclusions Intravenous tirofiban appears to be safe and effective when used following intra-arterial tirofiban or as monotherapy in AIS patients treated by endovascular therapy, which can improve the 90-day functional outcome, decrease the 90-day mortality and increase the possibility of early recanalization without increasing rates of sICH and ICH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
周佳雯完成签到 ,获得积分10
1秒前
1秒前
1秒前
彭于彦祖应助小达采纳,获得10
3秒前
小姜完成签到,获得积分10
3秒前
yookia应助诗亭采纳,获得10
3秒前
3秒前
lena发布了新的文献求助10
5秒前
SciGPT应助荔枝吖采纳,获得10
5秒前
zanzan完成签到,获得积分10
6秒前
小姜发布了新的文献求助10
6秒前
6秒前
桐桐应助刘向洋采纳,获得10
7秒前
顺带急完成签到 ,获得积分10
8秒前
月亮完成签到 ,获得积分10
8秒前
慢慢完成签到,获得积分10
8秒前
深院梧桐发布了新的文献求助30
8秒前
kedaya应助桃花嫣然采纳,获得30
10秒前
一只睿智Cat完成签到 ,获得积分10
11秒前
负责的谷云完成签到,获得积分10
11秒前
小妮发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
14秒前
dodo应助Zhangz采纳,获得200
15秒前
欢喜白亦完成签到 ,获得积分10
15秒前
似水流年完成签到 ,获得积分10
15秒前
尉迟希望发布了新的文献求助10
17秒前
17秒前
18秒前
zhang完成签到,获得积分10
18秒前
若杉发布了新的文献求助10
18秒前
19秒前
洺全完成签到,获得积分10
19秒前
可爱的函函应助活力书包采纳,获得10
19秒前
小郭发布了新的文献求助10
20秒前
ivying0209完成签到,获得积分10
21秒前
小妮完成签到,获得积分10
22秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961075
求助须知:如何正确求助?哪些是违规求助? 3507282
关于积分的说明 11135478
捐赠科研通 3239777
什么是DOI,文献DOI怎么找? 1790434
邀请新用户注册赠送积分活动 872379
科研通“疑难数据库(出版商)”最低求助积分说明 803150